JDRF To Collaborate with MediGene to Develop an Antigen-Specific Immunotherapeutic for Type I Diabetes
Type I diabetes is a disease caused by T cells that inappropriately destroy the body's own insulin-producing cells. MediGene's mTCR therapeutics engineer T cell receptors into antibody-like proteins that can be used to actively target known therapeutic compounds to target tissues. For its type I diabetes program, MediGene is developing specific mTCRs which will be used to both competitively block autoreactive T cell engagement to beta cells and to selectively target known immunosuppressive agents to the beta cell's local environment.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.